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Abstract  
Context: Portulacerebroside A (PCA) is a novel cerebroside compound isolated from 
Portulaca oleracea L. (Portulacaceae), an edible and medicinal plant widely 
distributed in the temperate and tropical zones of the world. 
Objective: The present study investigates the effects of PCA in human liver cancer 
HCCLM3 cells on metastasis and invasion, a leading factor resulting in cancer related 
deaths. 
Materials and methods: After the cells were treated with the designated 
concentrations of PCA (2.5, 5 and 10 μg/ml) for different times, adhesion, transwell 
invasion and scratch tests were conducted and cell functions evaluated. Western blot 
and FQ-RT-PCR assays were used to explore the mechanism of PCA-inhibited 
invasion and metastasis in the cells. 
Results: PCA significantly suppressed the adhesion rate in a dose-dependent manner 
whilst decreasing the invasion and migration of cells. There was an increase in the 
mRNA and protein expression levels of TIMP-2 and nm23-H1, an inhibition in the 
mRNA expression of MTA1, MMP-2 and MMP-9, and a suppression in the protein 
expression of MTA1, RhoA, Rac1/Cdc42, MMP-2, but not RhoC and MMP-9.  
Conclusion: PCA suppresses the invasion and metastasis of HCCLM3 cells possibly 
by modulation of the mRNA and protein expression of related parameters. This is the 
first study to reveal a new potential therapeutic application of PCA in anti-metastatic 
therapy for liver cancer.  
Key words: Natural product; Hepatoma; Aggression; Migration; Cell 
 
 
 
 
 
 
 
 
Introduction  
Portulaca oleracea L. (Portulacaceae) is an edible and medicinal plant widely 
distributed in the temperate and tropical zones of the world. Its aerial part (Chinese 
name Ma-Chi-Xian) has a long history of use in China for the prevention and 
treatment of diarrhea, urinary tract infection and diabetes. It is also used for clearing 
away heat and toxic materials from blood to stop bleeding and for relieving the 
symptoms of dysentery.  
Portulaca oleracea also displays a wide range of pharmacological properties, such 
as regulating lipidemia, anti-aging, neuroprotective, antidiabetic, antimicrobial, 
antioxidative, anti-inflammatory, anti-ulcerogenic, hepatoprotective, and analgesic 
activities (Xin et al., 2008; Yan et al., 2012). Several fractions obtained from this 
plant have been reported to display antitumor effects (Li et al., 2009). For example, 
Polysaccharides isolated from this plant have evidently scavenged accumulating free 
radicals and modulated immunity functions of rats with ovarian cancer (Chen et al., 
2009). Three homoisoflavonoids present in this plant display selectively 
cytotoxic activities towards four human cancer cell lines, especially 
2,2′-dihydroxy-4′,6′-dimethoxychalcone against gastric carcinoma SGC-7901 cells 
with an IC50 of 1.6 μg/ml, which is more potent than the reference compound 
mitomycin C which as IC50 of 13.0 μg/ml (Yan et al., 2012). Alkaloids, 
N-trans-feruloyltyramine, (7′R)-N-feruloylnormetanephrine, 
1,5-dimethyl-6-phenyl-1,2-dihydro-1,2,4-triazin-3(2H)-one and 
(3R)-3,5-bis(3-methoxy-4-hydroxyphenyl)-2,3-dihydro-2(1H)-pyridinone, revealed 
weak bioactivities against K562 with the IC50 values of 222.77, 66.94, 90.09, and 
41.52 μM, respectively, and moderate bioactivities against A549 with the IC50 values 
of 28.80, 21.76, 24.54, and 37.20 μM, respectively ( Tian et al., 2014). 
We have previously isolated a novel cerebroside compound named as 
portulacerebroside A (PCA, Figure 1) from Portulaca oleracea (Xin et al., 2008), 
which markedly inhibited cell viability, induced chromatin aggregation and 
fragmented nuclei, and enhanced the apoptotic percentage of human liver cancer 
HCCLM3 cells. Furthermore PCA remarkably increased the protein phosphorylation 
of p38 MAPK and JNK, disrupted mitochondrial membrane penetrability, and 
triggered the release of mitochondrial cytochrome C and AIF to cytosol in the cells. 
PCA also evidently activated caspase-9 and caspase-3, but not caspase-8. These 
results suggest that PCA-induced apoptosis is associated with activation of the p38 
MAPK- and JNK-triggered mitochondrial death pathway (Zheng et al., 2014). In the 
present study, we investigated the effects of PCA on invasive and metastasis in 
HCCLM3 cells and the possible underlying mechanism.  
Materials and methods 
Portulacerebroside A  
Portulacerebroside A (PCA) was isolated and purified from the aerial parts of 
Portulaca oleracea L. as reported previously (Xin et al., 2008) and appears as a white 
powder (Molecular formula: C48H93NO10; molecular weight: 843; purity: 98.1%). The 
appropriate amount of dimethylsulfoxide (DMSO) was used to dissolve PCA, and the 
final concentration of DMSO was kept below 0.1%. PCA was diluted to the desired 
concentrations before application and no differences were observed in cell growth 
between the cells treated with or without DMSO, indicating that DMEM containing 
0.1% DMSO had no effects on cell growth.  
Cell culture 
The human liver cancer HCCLM3 cells were obtained from JRDUN Biotechnology 
(Shanghai) Co., Ltd. (China), and were grown in DMEM containing 10% FBS and 
1% penicillin/streptomycin as described by our previous literature (Zheng et al., 2014). 
The cells were pre-incubated at 37°C in a humid atmosphere containing 5% CO2.  
Adhesion test 
A 96-well plate was used and 30 μl of BD Matrigel was added to each well and left to 
dry for 1 h. The plate was then rinsed 2X with PBS and 100 μl of PBS containing 1% 
fetal bovine serum (FBS) was then added to each well, incubated for 1 h in an 
incubator at 37oC followed by a further wash with 2X200 μl of PBS. The cells were 
pre-treated with PCA at concentrations 2.5, 5 and 10 μg/ml for 12 h and were then 
suspended in serum free DMEM to give a concentration of 1×105/ml followed by the 
addition of 100 μl/well of this suspension and the plate was finally incubated in an 
incubator for 0.5, 1 and 1.5h, respectively. The medium was removed from each well 
by aspiration and the cells were further washed 2X with PBS and 200 μl of DMEM 
containing 2% (v/v) FBS was added to each well. The OD value of each well was 
then measured using a CCK-8 assay and the results are presented as % of control.  
Transwell invasion test 
The cells were suspended in serum-free DMEM and pretreated with PCA at a 
concentration of 2.5, 5 and 10 μg/ml respectively for 6 h. A 24-well plate with 
transwell cabinets was soaked in PBS for 5 min prior to cell seeding and the bottom of 
cabinets was precoated with matrigel to form a genuine reconstituted basement 
membrane. After digestion with pancreatic enzymes and washing with serum free 
DMEM, the cells were suspended in DMEM containing 1% (v/v) FBS and seeded in 
transwell cabinets with 0.5 ml/cabinet at the density of 2×105/ml. This was followed 
by the addition of 0.75 ml of DMEM containing 10 % (v/v) FBS and the plate was 
placed in an incubator at 37oC for 24h. Subsequently 1 ml of 4% formaldehyde 
solution was added to each well and the cells were fixed for 10 min at room 
temperature. The excess stationary formaldehyde was then removed by aspiration and 
1 ml of 0.5% crystal violet solution was added to each well and the cells were stained 
for 30 min. Finally the cells were washed 3X with PBS, dried and images were taken 
by an Olympus inverted microscope (magnification, ×20) and invaded cells were 
quantified by manual counting.  
Migration test 
The HCCLM3 cells were seeded in a 6-well plate until 95% confluence was reached. 
The monolayer cells were subjected to a cross line wound by a sterile pipette tip and 
washed with 3X PBS to remove cell debris. The cells were then incubated at 37°C 
with PCA concentrations of 2.5, 5 and 10 μg/ml for 24 h and 48 h respectively. An 
inverted microscope was used to observe cell morphology and digital images (×10) 
were obtained and then the cells that migrated to the wound were quantified by 
manual counting. The experiment was repeated three times. 
Fluorescent quantitative reverse transcription-PCR (FQ-RT-PCR) 
After 24 h of incubation in a 6-well plate, the cells were treated with various 
concentrations of PCA for 6 h before being harvested. Total RNA was extracted using 
a TRIzol® Plus RNA Purification Kit (Invitrogen, China), which provides a simple, 
reliable, and a rapid method for isolating high-quality total RNA from cells. The 
isolated RNA was treated with RNase-free DNase (Promega, China).  
Reverse transcription was carried out using a cDNA synthesis kit (Thermo) in 
accordance with the manufacturer's instructions and as reported previously (Zhang et 
al. 2012a; Paul et al., 2013). PCR amplification was performed using a SYBR Green 
PCR kit (Thermo). Primer pairs for human genes were designed using the Primer 
Express Software (Applied Biosystems) and are listed in Table 1. Relative expression 
of mRNA (%) = 2−ΔCT(1,2,3,4,5) × 100%, where CT represents threshold cycle, ΔCT1 = 
CT(nm23-H1) − CT(GAPDH), ΔCT2 =CT(MTA1) − CT(GAPDH), ΔCT3 = CT(MMP-2) − 
CT(GAPDH), ΔCT4 = CT(MMP-9) − CT(GAPDH), ΔCT5 =CT(TIMP-2) − CT(GAPDH). 
Western blot assay  
After incubation with the designated concentrations of PCA for 24 h, the cells were 
washed and suspended at 4°C for 20 min. Following centrifugation, the supernatant 
was transferred to a microtube and the protein concentration was measured using a 
BCA protein assay kit (Thermo). Protein expression was detected by Western blot 
hybridization in accordance with the manufacturer’s instructions and as reported 
previously (Zhang et al., 2012b). 
Statistical analysis 
All results are presented as the mean ± SD and the data were analyzed using a SPSS 
13.0 statistical package. Data for multiple comparisons were subjected to one-way 
ANOVA followed by Dunnett’s test and a value of P < 0.05 was considered 
statistically significant. 
Results  
PCA depresses the adhesion of HCCLM3 cells  
As shown in Figure 2, the adhesive rate of cells descended in a time and dose 
dependent manner after 12 h of pre-treatment with PCA (2.5, 5 and 10 μg/ml) at 0.5h 
(79.4 ± 1.0%, 68.7 ± 1.3% and 58.1 ± 1.3%, respectively, versus 100 ± 1.5% in the 
control group; all p < 0.01 ), 1 h (78.2 ± 1.2%, 70.9 ± 1.6% and 55.4 ± 1.9%, 
respectively, versus 100 ± 1.2% in the control group; all p < 0.01 ), and 1.5 h (71.6 ± 
1.1%, 62.3 ± 0.9% and 50.4 ± 0.9%, respectively, versus 100 ± 1.1% in the control 
group; all p < 0.01 ). The PCA treatment significantly reduced the adhesive ability of 
HCCLM3 cells when compared to the control cells (untreated cells).  
PCA inhibits the invasion of HCCLM3 cells 
For pervasion to distant organs, the invasion of tumor cells occurs via cell-secreted 
proteolytic degradation of the cellular basement membrane, which is the leading cause 
of cancer death. The Transwell Invasion test results are presented in Figure 3.  
Pretreatment with PCA (2.5 5 and 10 μg/ml) for 6 h significantly suppressed the 24 h 
invasion ability of cells in a dose-dependent manner when compared to the control 
group of untreated cells (356.6 ± 11.2%, 204.0 ± 17.6% and 113.0 ± 9.5%, 
respectively, versus 443.6 ± 15.4% in the control group; all p < 0.01 ).  
PCA prevents HCCLM3 cells from migration 
The effects of PCA on chemotactic motility in cells were evaluated by the Scratch test. 
As displayed in Figure 4A, the migrated cells decreased dramatically and 
dose-dependently after treatment with designated concentrations of PCA (2.5, 5 and 
10 μg/ml) for 24 h (324.8 ± 25.4, 250.4 ± 21.0 and 126.3 ±10.1, respectively, versus 
381.6 ± 30.6 in the control group; all p < 0.01) and 48 h (470.3 ± 34.3, 404.0 ± 19.7 
and 201.0 ±15.4, respectively, versus 752.0 ± 63.6 in the control group; all p < 0.01), 
respectively. Typical images of PCA inhibiting cell migration are presented in Figures 
4B and 4C. 
PCA regulates the mRNA expression of metastasis-related parameters in 
HCCLM3 cells 
The effects of PCA on the mRNA expression of nm23-H1, MTA1, MMP-2, MMP-9 
and TIMP-2, which are closely related to metastasis of tumor cells, were also 
investigated and the results are presented in Table 2. As a result, 6 h of PCA treatment 
significantly increased the expression of nm23-H1 and TIMP-2 and reduced the 
expression of MTA1, MMP-2 and MMP-9 in a dose-dependent manner.  
PCA adjusts the metastasis-related protein expression in HCCLM3 cells 
After 24 h of PCA treatment, the metastasis-related protein expression in cells was 
analyzed by western blot. As shown in Figure 5, PCA (5 and 10μg/ml) significantly 
increased the expression levels of nm23-H1 (0.58 ± 0.04 and 0.52 ± 0.04, respectively, 
versus 0.17 ± 0.01 in the control group; all p < 0.01) and TIMP-2  (0.49 ± 0.04 and 
0.62 ± 0.05, respectively, versus 0.26 ± 0.02 in the control group; p < 0.05 or p <0.01), 
decreased the expression levels of MTA1 (0.56 ± 0.03 and 0.45 ± 0.03, respectively, 
versus 0.74 ± 0.05 in the control group; all p < 0.05), RhoA (0.36 ± 0.02 and 0.38 ± 
0.02, respectively, versus 0.55 ± 0.04 in the control group; all p < 0.05), Rac/Cdc42 
(0.32 ± 0.03 (p > 0.05) and 0.26 ± 0.01 (p < 0.05), respectively, versus 0.26 ± 0.02 in 
the control group) and MMP-2 (0.30 ± 0.02 and 0.15 ± 0.01, respectively, versus 0.67 
± 0.05 in the control group; all p < 0.01). However, no effect on MMP-9 expression 
was evident (0.47 ± 0.04 and 0.41 ± 0.03, respectively, versus 0.44 ± 0.04 in the 
control group; all p > 0.05). Although RhoC expression was suppressed by PCA, this 
was not statistically significant (0.58 ± 0.04 and 0.50 ± 0.04, respectively, versus 0.65 
± 0.07 in the control group; all p >0.05). 
Discussion 
A leading cause of death in cancer patients is tumor metastasis, due to failure of 
complete removal of tumor tissue during surgery and radiotherapy. Although there are 
numerous chemical drugs of choice used in chemotherapy, too many side effects or 
uncertain actions impede their clinical applications hence it is necessary to search for 
novel anti-tumor agents. Portulacerebroside A (PCA), a novel natural compound 
isolated from Portulaca oleracea, is reported to significantly elicit HCCLM3 cell 
apoptosis (Zheng et al., 2014), although the PCA-modulated tumor migration and 
invasion was not investigated. In the present study, PCA significantly inhibited the 
adhesion, invasion and migration of HCCLM3 cells at doses of 2.5, 5 and 10 μg/ml in 
a dose dependent manner. This suggests that PCA not only induces apoptosis of tumor 
cells, but also prevents them from metastasis, subsequently in this paper we report the 
possible mechanisms involved. 
Metastasis-associated gene 1 (MTA1), an integral part of the nucleosome 
remodeling and histone deacetylation (NuRD) complex, can inhibit the transcription 
of target genes by recruiting histone deacetylases into the promoter regions of target 
genes thus inducing histone deacetylation (Li et al., 2013). MTA1 is up-regulated in 
human tumors (Hofer et al., 2006) and increases the metastatic and invasive potential 
of carcinoma cells (Kumar et al., 2003; Hofer et al., 2004; Toh et al., 2004; Zhang et 
al., 2014). In this study, PCA evidently inhibited the mRNA and protein expression of 
MTA1.  
 Many biological functions are associated with nm23-H1, which can inhibit tumor 
metastasis (Novak et al., 2011) and is also capable of binding to DNA leading to the 
regulation of gene expression (Choudhuri et al., 2010; Thakur et al., 2009).  The 
exogenous expression of nm23-H1 in cells without endogenous nm23-H1 expression 
not only suppresses migration and invasion, but also decreases cell proliferation and 
anchorage independent growth (McDermott et al., 2008; Jung et al., 2006). Moreover 
nm23-H1 protein inhibits telomerase activity (Kar et al., 2012) and increases cell-cell 
adhesion (Bago et al., 2009), cell-cycle arrest, and apoptosis (Cervoni et al., 2006). 
This suggests that nm23-H1 plays an important role in the process of tumor formation 
and metastasis. Therefore we further analyzed the mRNA and protein expression of 
nm23-H1, both of which were markedly increased by PCA treatment.  
The extracellular matrix (ECM) regulates cell attachment, motility, invasion, and 
metastasis (Kumar et al., 2010). Degradation of ECM is performed by matrix 
metalloproteinases (MMPs), especially MMP-2 and MMP-9, which play a key role in 
degrading basement membranes and cancer invasion and metastasis (Gialeli et al., 
2011; Iguchi et al., 2012), but are regulated by TIMPs, the endogenous inhibitors of 
the zinc-dependent endopeptidases of MMPs (Rubaci et al., 2012). In the present 
study, PCA raised the mRNA and protein expression of TIMP-2, suppressed the 
protein expression of MMP-2 and the mRNA expression of MMP-2 and MMP-9, 
however, it did not repress the protein expression of MMP-9 in HCCLM3 cells. These 
findings indicate that the anti-metastatic effects of PCA in tumor cells are associated 
with regulation of the MMP/TIMP balance.  
RhoA and RhoC, are GTPases and are part of the extensive Ras superfamily, have 
92% amino acid identity and interact with various regulators and effectors with 
modulation activity to regulate invasion, metastasis, actin cytoskeleton, cell 
proliferation, oncogenesis, and survival of cells (Rathinam et al., 2011; Mardilovich 
et al., 2012). RhoA and RhoC have been extensively documented for migration and 
invasion (Faried et al., 2007; Liu et al., 2012; Struckhoff et al., 2011). RhoA 
expression is increased in human breast cancers due to miRNAmiR-31 suppression, 
and metastasis in mouse models has also been reported (Valastyan et al., 2009). 
Deletion of RhoC does not affect breast cancer growth in a mouse model, but 
metastasis is significantly impaired (Hakem et al., 2005). RhoC mRNA is one of the 
targets of miRNA miR-493 and miR-138, both of which decrease the migration of 
tumor cells (Jiang et al., 2010; Ueno et al., 2012). Rac1 and Cdc42 also belong to 
GTPases and take part in the control of cell migration (Zins et al., 2013), activation of 
which is required for HER2/ErbB2-elicited migration and invasion of breast cancer 
cells (Johnson et al., 2010). Therefore we investigated the protein expression levels of 
RhoA, RhoC and Rac1/Cdc42 in the cells. As a result, treatment with PCA for 24 h 
remarkably depressed the expression of RhoA and Rac1/Cdc42 but not RhoC, 
indicating that PCA-induced migration and invasion had no direct involvement in 
RhoC.  
In conclusion, our investigation has demonstrated for the first time the inhibitory 
effects of PCA on the metastatic and invasive capabilities of human hepatoma 
HCCLM3 cells. The possible mechanisms involved are that PCA increases the 
expression of TIMP-2 and decreases the expression of MMP-2, RhoA, RhoC and 
Rac1/Cdc42 through modulation of the metastasis promoting gene MTA1 and 
metastasis suppressor gene nm23-H1. These findings reveal a new potential 
therapeutic application of PCA in anti-metastatic therapy for liver cancer.  
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Figures and Tables 
 
Figure 1 The chemical structure of portulacerebroside A (PCA) 
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Figure 2 Effects of portulacerebroside A on adhesive ability of HCCLM3 cells. The cells were 
pre-treated with various concentrations of Portulacerebroside A (PCA) for 12 h in a 96-well plate 
and the adhesion rate of the cells was determined at 0.5 h, 1 h and 1.5 h, respectively. **, ΔΔ, †† 
p<0.01 compared with the control group. Data are expressed as the mean ± SD. n = 6. 
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Figure 3 Effects of portulacerebroside A on invasive ability of HCCLM3 cells. After 6 h of 
pretreatment with designated concentrations of portulacerebroside A (PCA), the cells were 
incubated in transwell cabinets for a further 24 h, and the invasive cell number (A) was counted. 
(B) Representative images (×20) for each group. ** p<0.01 compared with the control group. Data 
are expressed as the mean ± SD. n = 6.  
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Figure 4 Effects of portulacerebroside A on migration ability of HCCLM3 cells. The cells 
were subjected to a cross line wound by a sterile pipette tip in a 6-well plate and were then 
incubated with designated concentrations of portulacerebroside A (PCA) for 24 h and 48 h, 
respectively. The migration cells were then counted (A). (B) and (C) display typical images (×10)                        
of cells treated with PCA. **, ΔΔ p<0.01 compared with the control group. Data are expressed as 
the mean ± SD. n = 6. 
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Figure 5 Effects of portulacerebroside A on the protein expression of metastasis-related 
parameters. After 24 h of treatment with portulacerebroside A (PCA), the protein expression of 
MTA1 (A), nm23-H1 (A), RhoC (B), RhoA (B), Rac1/Cdc42 (B), MMP-2 (C), MMP-9 (C) and 
TIMP-2 (C) was detected by western blot. (D) Representative western blot images of HCCLM3 
cells treated with PCA. *, Δ p<0.05; **, ΔΔ p<0.01 compared with the control group. Data are 
expressed as the mean ± SD. n = 3.  
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Table 1  Primers used in FQ-RT-PCR analysis 
Gene Primer sequence Species Amplicon size (bp) 
Nm23-H1 Forward: 5′ GTGAGCGTACCTTCATTGC 3′ Human 249 
 Reverse: 5′ CCGTCTTCACCACATTCAG 3′   
MTA1 Forward: 5' CTTGAAGCTGATGGTGAATG 3' 
Reverse: 5′ AGAGTTGTACCCTGAAGTTG 3′ 
Human 134 
MMP-2 Forward: 5′ TTGACGGTAAGGACGGACTC 3′ Human 134 
 Reverse: 5′ GGCGTTCCCATACTTCACAC 3′   
MMP-9 Forward: 5′ AAGGGCGTCGTGGTTCCAACTC 3′ Human 210 
 Reverse: 5′ AGCATTGCCGTCCTGGGTGTAG 3′   
TIMP-2 Forward: 5′ TTCGTCTCCCGTCTTTGG 3′ 
Reverse: 5′ TTTGAGCGGCTTCCTCTG 3′ 
Human 
 
185 
GAPDH Reverse: 5′ CACCCACTCCTCCACCTTTG 3′ Human 110 
 Reverse: 5′ CCACCACCCTGTTGCTGTAG 3′   
 
 
Table 2 Effects of PCA on the mRNA expression of metastasis-related parameters 
Group    Dose    nm23-H1      MTA1        MMP-2      MMP-9      TIMP-2 
(μg/ml)    (%)          (%)           (%)         (%)         (%)        
Control   ----    4.85±0.47     57.44±3.93    13.21±1.46   7.72±0.38     1.59±0.26 
PCA     2.5     9.23±0.86**   23.28±2.02**   6.74±0.64**   3.67±0.05**   5.14±0.35** 
PCA     5      13.34±1.67**   11.75±1.85**   3.95±0.37**   2.70±0.18**   9.81±0.45** 
PCA     10     19.50±1.08**   6.33±0.77**    1.37±0.17**   0.91±0.09**   13.96±1.24** 
After HCCLM3 cells were treated with various concentrations of PCA for 6 h, the mRNA 
expression of metastasis-related parameters was detected by FQ-RT-PCR. **P<0.01 compared 
with the control group; Data are expressed as the mean ± SD. n = 6. 
 
 
 
 
